Sinvisc 2 ml syringe, 3 pcs.

Sinvisk is a chondroprotective drug that prostitutes synovial fluid. The drug consists of the active ingredient – hyaluronic acid derivative Gilan. The prosthesis is available as a visco-elastic solution in sterile syringes of 2 ml each.

Synvisc is a biological analogue of hyaluronate, a component of synovial fluid that provides the visco-elastic characteristics of intra-articular fluid. The mechanical properties of Gilan are superior to those of natural hyaluronate synovial fluid and hyaluronic acid solution at similar concentrations. Gilan is excreted from the body by the same ways as hyaluronate, the breakdown products of hyaluronate are not toxic.

Synvisc replenishes fluid viscosity, which improves the rheological and physiological state of the tissues of the diseased joint. Synvisk reduces pain and discomfort caused by dystrophic changes in cartilage tissues, thus improving mobility in the joint. The ability of the drug to protect cartilage from chemical and mechanical damage has been proven.

< br>.

Indications

temporary replenishment or replacement of synovyl fluid;
treatment of patients suffering from osteoarthritis of the knee joint (gonarthrosis) at any stage of the disease;
effective recovery of patients who constantly load their joints and lead an active lifestyle (athletes, workers engaged in heavy physical labor);
exclusively intra-articular injection for pain relief in osteoarthritis of the knee joint.

Pharmacological effect

Synvisc is a chondroprotective drug that protects synovial fluid. The drug also consists of an active substance – hylan, which is a derivative of hyaluronic acid. The prosthesis is produced in the form of a viscoelastic solution in sterile syringes of 2 ml each.

Synvisc is a biological analogue of hyaluronate, a component of synovial fluid, which provides the viscoelastic characteristics of the intra-articular fluid. The mechanical properties of hylan are higher than natural synovial fluid hyaluronate and hyaluronic acid solution in similar concentrations. Gilan is excreted from the body in similar ways as hyaluronate; the breakdown products of hylan are not toxic.

Synvisc replenishes the viscosity of the fluid, which improves the rheological and physiological state of the tissues of the diseased joint. Synvisc reduces pain and discomfort caused by dystrophic changes in cartilage tissue, thereby improving mobility in the joint. The ability of the drug to protect cartilage from chemical and mechanical damage has been proven.

Special instructions

Synvisc should not be administered if there is significant intra-articular effusion.

As with any other invasive joint procedure, after injection of Synvisc the patient is advised to adhere to a gentle regimen and avoid excessive stress on the joint for several days.

Synvisc contains small amounts of chicken protein, so caution should be used when treating patients with relevant hypersensitivity.

The effectiveness of a course of treatment containing less than three injections has not been established.

The effectiveness and safety of Synvisc when used on joints other than the knee and for indications other than osteoarthritis has not been established.

Synvisc has not been used to treat pregnant women and children under 18 years of age.

During the course of treatment with Synvisc, it is not allowed to introduce anesthetics or other pharmacological drugs into the cavity of the affected joint.

Composition

1 ml contains:

hylan 8.0 mg;

sodium chloride 8.5 mg;

sodium hydrogen phosphate 0.16 mg;

sodium dihydrogen phosphate hydrate 0.04 mg;

water for injections.

Contraindications

venous and lymphatic stasis present in the area of ​​the affected joint;
the presence of an infected and inflamed joint, signs of skin infection directly in the area where the solution is supposed to be administered;
allergic reactions and hypersensitivity to sodium hyaluronate;
pregnancy and breastfeeding.

Side Effects

After injection of Synvisc, there may be short-term pain, swelling in the injection area and/or the appearance of intra-articular exudation. In some cases, exudation can be significant and cause more prolonged pain.

In these cases, it is necessary to puncture the joint and remove the exudate, followed by microscopy in order to exclude infection and microcrystalline arthropathy (gout). Typically, such reactions disappear without a trace within a few days and do not affect the effectiveness of treatment.

During clinical trials of the drug, no cases of infection were observed after injections of Synvisc, and only a few such cases were reported during clinical use.

Interaction

When treating the skin before injection, you should not use disinfectants containing quaternary ammonium salts.

Storage conditions

Store at temperatures between 2 °C and 30 °C. Do not freeze.

Manufacturer

Genzyme Europe B.V., USA